Development of a New Reverse Genetics System for Ebola Virus.

Tianyu Gan, Dihan Zhou, Yi Huang, Shuqi Xiao, Ziyue Ma, Xiaoyou Hu, Yimin Tong, Huimin Yan, Jin Zhong
Author Information
  1. Tianyu Gan: Unit of Viral Hepatitis, CAS Key Laboratory of Molecular Virology and Immunology, Institut Pasteur of Shanghai, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Shanghai, China.
  2. Dihan Zhou: The Joint Laboratory for Translational Precision Medicine, Guangzhou Women and Children's Medical Center, Guangzhou, China, and Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, China.
  3. Yi Huang: Wuhan National Biosafety Laboratory, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, China.
  4. Shuqi Xiao: Wuhan National Biosafety Laboratory, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, China.
  5. Ziyue Ma: Unit of Viral Hepatitis, CAS Key Laboratory of Molecular Virology and Immunology, Institut Pasteur of Shanghai, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Shanghai, China.
  6. Xiaoyou Hu: Unit of Viral Hepatitis, CAS Key Laboratory of Molecular Virology and Immunology, Institut Pasteur of Shanghai, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Shanghai, China.
  7. Yimin Tong: Unit of Viral Hepatitis, CAS Key Laboratory of Molecular Virology and Immunology, Institut Pasteur of Shanghai, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Shanghai, China.
  8. Huimin Yan: Mucosal Immunity Research Group, State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, China hmyan@wh.iov.cn jzhong@ips.ac.cn. ORCID
  9. Jin Zhong: Unit of Viral Hepatitis, CAS Key Laboratory of Molecular Virology and Immunology, Institut Pasteur of Shanghai, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Shanghai, China hmyan@wh.iov.cn jzhong@ips.ac.cn. ORCID

Abstract

Ebola virus (EBOV) is a highly pathogenic negative-stranded RNA virus that has caused several deadly endemics in the past decades. EBOV reverse genetics systems are available for studying live viruses under biosafety level 4 (BSL-4) or subviral particles under BSL-2 conditions. However, these systems all require cotransfection of multiple plasmids expressing viral genome and viral proteins essential for EBOV replication, which is technically challenging and unable to naturally mimic virus propagation using the subviral particle. Here, we established a new EBOV reverse genetics system only requiring transfection of a single viral RNA genome into an engineered cell line that stably expresses viral nucleoprotein (NP), viral protein 35 (VP35), VP30, and large (L) proteins and has been fine-tuned for its superior permissiveness for EBOV replication. Using this system, subviral particles expressing viral VP40, glycoprotein (GP), and VP24 could be produced and continuously propagated and eventually infect the entire cell population. We demonstrated the authentic response of the subviral system to antivirals and uncovered that the VP35 amount is critical for optimal virus replication. Furthermore, we showed that fully infectious virions can be efficiently rescued by delivering the full-length EBOV genome into the same supporting cell, and the efficiency is not affected by genome polarity or virus variant specificity. In summary, our work provides a new tool for studying EBOV under different biosafety levels. Ebola virus is among the most dangerous viral pathogens, with a case fatality rate of up to 90%. Since 2013, the two largest and most complex Ebola outbreaks in Africa have revealed the lack of investigation on this notorious virus. A reverse genetics system is an important tool for studying viruses by producing mutant viruses or generating safer and convenient model systems. Here, we developed an EBOV life cycle modeling system in which subviral particles can spontaneously propagate in cell culture. In addition, this system can be employed to rescue infectious virions of homologous or heterologous EBOV isolates using either sense or antisense viral RNA genomes. In summary, we developed a new tool for EBOV research.

Keywords

References

  1. Nature. 2014 Oct 2;514(7520):47-53 [PMID: 25171469]
  2. Virology. 2015 Oct;484:259-264 [PMID: 26122472]
  3. EMBO J. 1995 Dec 1;14(23):5773-84 [PMID: 8846771]
  4. J Virol. 1999 Mar;73(3):2333-42 [PMID: 9971816]
  5. J Infect Dis. 2007 Nov 15;196 Suppl 2:S284-90 [PMID: 17940962]
  6. Curr Top Microbiol Immunol. 2017;411:421-445 [PMID: 28918537]
  7. Nature. 2016 Mar 17;531(7594):381-5 [PMID: 26934220]
  8. J Virol. 2014 Sep;88(18):10511-24 [PMID: 24965473]
  9. J Infect Dis. 2011 Nov;204 Suppl 3:S878-83 [PMID: 21987764]
  10. J Virol. 2005 Feb;79(3):1898-905 [PMID: 15650213]
  11. Nat Rev Microbiol. 2020 Jul;18(7):365-378 [PMID: 32367066]
  12. Arch Virol. 2019 Apr;164(4):1233-1244 [PMID: 30663023]
  13. PLoS Pathog. 2015 Nov 12;11(11):e1005263 [PMID: 26562011]
  14. EMBO J. 1994 Sep 15;13(18):4195-203 [PMID: 7925265]
  15. Nat Rev Microbiol. 2015 Nov;13(11):663-76 [PMID: 26439085]
  16. J Virol. 2006 Jul;80(14):7260-4 [PMID: 16809331]
  17. Virology. 2005 Feb 5;332(1):20-7 [PMID: 15661137]
  18. Proc Natl Acad Sci U S A. 1995 Aug 29;92(18):8388-92 [PMID: 7667300]
  19. Proc Natl Acad Sci U S A. 1996 Dec 24;93(26):15400-4 [PMID: 8986823]
  20. Virology. 1998 Jul 20;247(1):1-6 [PMID: 9683565]
  21. Expert Rev Anti Infect Ther. 2014 Oct;12(10):1253-63 [PMID: 25169588]
  22. J Med Virol. 1979;4(3):201-11 [PMID: 94087]
  23. J Virol. 2002 Jan;76(1):406-10 [PMID: 11739705]
  24. J Infect Dis. 1999 Feb;179 Suppl 1:S224-34 [PMID: 9988188]
  25. J Virol. 2002 May;76(10):4855-65 [PMID: 11967302]
  26. J Virol. 2006 Jun;80(11):5156-67 [PMID: 16698996]
  27. J Infect Dis. 2011 Nov;204 Suppl 3:S941-6 [PMID: 21987773]
  28. J Virol. 2004 Jan;78(2):999-1005 [PMID: 14694131]
  29. Lancet. 2019 Mar 2;393(10174):936-948 [PMID: 30777297]
  30. Proc Natl Acad Sci U S A. 2008 Jan 29;105(4):1129-33 [PMID: 18212124]
  31. J Virol. 2003 Feb;77(3):1793-800 [PMID: 12525613]
  32. J Infect Dis. 2017 May 1;215(9):1416-1420 [PMID: 28368541]
  33. Nat Rev Drug Discov. 2018 Jun;17(6):413-434 [PMID: 29375139]
  34. J Infect Dis. 2013 Jul 15;208(2):310-8 [PMID: 23255566]
  35. Annu Rev Virol. 2019 Sep 29;6(1):435-458 [PMID: 31567063]
  36. J Virol. 2017 Oct 27;91(22): [PMID: 28878087]

MeSH Term

Cell Line
Ebolavirus
Genome, Viral
RNA, Viral
Reverse Genetics
Virology

Chemicals

RNA, Viral

Word Cloud

Created with Highcharts 10.0.0EBOVvirusviralsystemEbolasubviralRNAreversegeneticsgenomecellsystemsstudyingvirusesparticlesreplicationnewcantoolnegative-strandedbiosafetyexpressingproteinsusingVP35infectiousvirionssummarydevelopedhighlypathogeniccausedseveraldeadlyendemicspastdecadesavailablelivelevel4BSL-4BSL-2conditionsHoweverrequirecotransfectionmultipleplasmidsessentialtechnicallychallengingunablenaturallymimicpropagationparticleestablishedrequiringtransfectionsingleengineeredlinestablyexpressesnucleoproteinNPprotein35VP30largeLfine-tunedsuperiorpermissivenessUsingVP40glycoproteinGPVP24producedcontinuouslypropagatedeventuallyinfectentirepopulationdemonstratedauthenticresponseantiviralsuncoveredamountcriticaloptimalFurthermoreshowedfullyefficientlyrescueddeliveringfull-lengthsupportingefficiencyaffectedpolarityvariantspecificityworkprovidesdifferentlevelsamongdangerouspathogenscasefatalityrate90%Since2013twolargestcomplexoutbreaksAfricarevealedlackinvestigationnotoriousimportantproducingmutantgeneratingsaferconvenientmodellifecyclemodelingspontaneouslypropagatecultureadditionemployedrescuehomologousheterologousisolateseithersenseantisensegenomesresearchDevelopmentNewReverseGeneticsSystemVirusfilovirus

Similar Articles

Cited By